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CROSS-REFERENCE TO RELATED 
APPLICATIONS 
U.S. This application is a division of U.S. Ser. No. 
09/158,216, filed on Sep. 22, 1998 (now U.S. Pat. No. 
6,271,010), and claims the benefit of U.S. provisional appli 
cation no. 60/062,659, filed on Oct. 8, 1997, and priority 
from Danish application no. 1098/97, filed on Sep. 24, 1997. 
TECHNICAL FIELD 
The present invention relates to variants of cyclomalto 
dextrin glucanotransferase of increased product specificity. 
BACKGROUND ART 
Cyclomaltodextrin glucanotransferase (E.C. 2.4.1.19), 
also designated cyclodextrin glucanotransferase or cyclo 
dextrin glycosyltransferase, in the following termed 
CGTase, catalyses the conversion of Starch and Similar 
Substrates into cyclomaltodextrins via an intramolecular 
transglycosylation reaction, the reby forming 
cyclomaltodextrins, in the following termed cyclodextrins 
(or CD), of various sizes. Commercially most important are 
cyclodextrins of 6, 7 and 8 glucose units, which are termed 
Cl-, 3-, and Y-cyclodextrins, respectively. Commercially leSS 
important are cyclodextrins of 9, 10, and 11 glucose units, 
which are termed Ö-, e-, and -cyclodextrins, respectively. 
Cyclodextrins are thus cyclic glucose oligomers with a 
hydrophobic internal cavity. They are able to form inclusion 
complexes with many Small hydrophobic molecules in aque 
ous Solutions, resulting in changes in physical properties, 
e.g. increased Solubility and Stability and decreased chemi 
cal reactivity and volatility. Cyclodextrins find applications 
particularly in the food, cosmetic, chemical and pharmaceu 
tical industries. 
Most CGTases have both starch-degrading activity and 
transglycosylation activity. Although Some CGTaseS pro 
duce mainly C-cyclodextrins and Some CGTaseS produce 
mainly B-cyclodextrins, CGTases usually form a mixture of 
Cl-, 3- and Y-cyclodextrins. Selective precipitation Steps with 
organic Solvents may be used for the isolation of Separate Cl-, 
B- and Y-cyclodextrins. To avoid expensive and environmen 
tally harmful procedures, the availability of CGTases 
capable of producing an increased ratio of one particular 
type of cyclodextrin, in particular with respect to C-, 3- or 
Y-cyclodextrin, is desirable. 
WO 96/33267 (Novo Nordisk) describes CGTase variants 
showing a modified Substrate binding and/or product Selec 
tivity. Although CGTase variants produced by mutation at 
positions 47, 145, 146, 147, 196 or 371 have been described, 
the specific CGTase variants of this invention have never 
been described or even Suggested. 
SUMMARY OF THE INVENTION 
The present invention provided novel CGTase variants of 
increased product specificity. Although CGTase variants of 
increased product Specificity have been described in the 
prior art (WO 96/33267), the CGTase variants of the present 
invention have never been described or Suggested. 
Among the tremendous number of possible CGTase vari 
ants we have now Succeeded in finding a limited number of 
variants showing increased product specificity when com 
pared to the wild-type enzyme. 
Accordingly the invention provides a CGTase variant of 











amino acid residues corresponding to the following posi 
tions have been introduced by Substitution and/or insertion (CGTase Numbering): 
(i) Position 47: 47C; 47D; 47E; 47F; 47G; 47I; 47K: 47N; 
47P; 47R; 
47S; 47T; 47V; 47W, or 47Y; 
(ii) Position 145: 145D; 145H; 145I; 145N; 1450; or 145V: 
(iii) Position 146: 146H, 146K; 146L; 146T; 146V; or 146Y; 
(iv) Position 147: 147C; 147D; 147E; 147N; 1470; 
(v) Position 196: 196C; 196E; 196F; 196G; 196H; 196I; 
196K; 196L; 196M; 196P; 196O; 196R; 196T; 196V; or 
196W; 196Y and/or 
(vi) Position 371: 371C; 371E; 371F; 371H; 371I; 371K; 
371L: 371M; 371O; 371R; 371T; 371V; or 371W. 
Amino Acids 
In the context of this invention the following symbols and 






















B=ASX=Asp or ASn 
Z=Glx=Glu or Glin 
X=Xaa-Any amino acid 
*=Deletion or absent amino acid 
CGTase Variants 
A CGTase variant of this invention is a CGTase variant or 
mutated CGTase, having an amino acid Sequence not found 
in nature. 
A CGTase variant or mutated CGTase of this invention 
may be considered a functional derivative of a precursor 
CGTase enzyme (i.e. the native, parental, or wild-type 
enzyme), and may be obtained by alteration of a DNA 
nucleotide Sequence of a precursor gene or its derivatives, 
encoding the precursor enzyme. The CGTase variant or 
mutated CGTase may be expressed and produced when the 
DNA nucleotide Sequence encoding the CGTase variant is 
inserted into a Suitable vector in a Suitable host organism. 
The host organism is not necessarily identical to the organ 
ism from which the precursor gene originated. 
In the literature, enzyme variants have also been referred 
to as mutants or muteins. 
CGTase Numbering 
In the context of this invention a specific numbering of 
amino acid residue positions in CGTase enzymes is 
US 6,777.215 B2 
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employed. By alignment of the amino acid Sequences of 
various known CGTases it is possible to unambiguously 
allot a CGTase amino acid position number to any amino 
acid residue position in any CGTase enzyme, which amino 
acid Sequence is known. 
Using the numbering System originating from the amino 
acid sequence of the CGTase obtained from Bacillus circu 
lans Strain 251, aligned with the amino acid Sequence of a 
number of other known CGTases, it is possible to indicate 
the position of an amino acid residue in a CGTase enzyme 
unambiguously. 
This CGTase Numbering system has been described in 
WO 96/33267, and its equivalent, U.S. Pat. No. 6,004,790, 
see Table 1, pages 9-31 (in which table Bacillus circulans 
Strain 251 is represented as a). Table 1 of WO 96/33267 and 
its equivalent U.S. Pat. No. 6,004,790 also show the protein 
Sequences of a number of relevant CGTase and is hereby 
incorporated by reference. 
In describing the various CGTase variants produced or 
contemplated according to the invention, the following 
nomenclatures are adapted for ease of reference: 
original amino acid; Position; Substituted amino acid 
Accordingly, the Substitution of Serine with alanine in 
position 145 is designated as S145A. 
Amino acid residues which represent insertions in relation 
to the amino acid sequence of the CGTase from Bacillus 
circulans Strain 251, are numbered by the addition of letters 
in alphabetical order to the preceding CGTase number, Such 
as e.g. position 91aF for the “insert Phe between Thr at 
position 91 and Gly at position 92 of the amino acid 
Sequence of the CGTase from Thermoanaerobacter Sp. 
ATCC 53627, cf. Table 1 (). 
Deletion of a proline at position 149 is indicated as P149*, 
and an insertion between position 147 and 148 where no 
amino acid residue is present, is indicated as * 147aD for 
insertion of an aspartic acid in position 147a. 
Multiple mutations are separated by Slash marks ("/"), e.g. 
S145A/D 147L, representing mutations in positions 145 and 
147 Substituting Serine with alanine and aspartic acid with 
leucine, respectively. 
If a Substitution is made by mutation in e.g. a CGTase 
derived from a strain of Bacillus circulans, the product is 
designated e.g. “B. circulans/S145A'. 
All positions referred to in this application by CGTase 
numbering refer to the CGTase numbers described above. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The present invention is further illustrated by reference to 
the accompanying drawing, in which: 
FIG. 1 shows a cartoon of the substrate binding cleft of B. 
circulans St. 251 CGTase. Dote lines indicate hydrogen 
bonds between the enzyme (water) and the substrate. Cleav 
age point is defined between glucose residue -1 and 1. 
FIG. 2, 3 and 4 show cyclodextrins formed during incu 
bation of (mutant) CGTase proteins from Thermoanaero 
bacterium thermosulfurigenes. A. wild-type (FIG. 2); B. 
Variant D196H (FIG. 3); C. variant D371R (FIG. 4). 
DETAILED DISCLOSURE OF THE INVENTION 
The present invention provides novel CGTase variants, 
i.e. CGTase variants having an amino acid Sequence not 
found in nature. Formally, the CGTase variant of the inven 
tion may be regarded as a functional derivative of a precur 
Sor CGTase enzyme (i.e. the native, parental, or wild-type 
enzyme), by Substitution, insertion and/or deletion of one or 











In the context of this invention, a CGTase variant of 
increased product specificity is a CGTase variant capable of 
producing an increased ratio of one particular type of 
cyclodextrin, when compared to the wild-type enzyme. 
In a CGTase variant of the invention, one or more amino 
acid residues corresponding to the following positions 
(CGTase Numbering) have been introduced by substitution 
and/or insertion: 
(i) Position 47: 47C; 47D; 47E; 47F; 47G; 47I; 47K: 47N; 
47P; 47R; 47S; 47T; 47V; 47W, or 47Y; 
(ii) Position 145: 145D; 145H; 145I; 145N; 1450; or 145V: 
(iii) Position 146: 146H, 146K; 146L; 146T; 146V; or 146Y; 
(iv) Position 147: 147C; 147D; 147E; 147N; 1470; 
(v) Position 196: 196C; 196E; 196F; 196G; 196H; 196I; 
196K; 196L; 196M; 196P; 196O; 196R; 196T, 196V; 
196W; or 196Y and/or 
(vi) Position 371: 371C; 371E; 371F; 371H; 371I; 371K; 
371L: 371M; 371O; 371R; 371T; 371V; or 371W. 
In a preferred embodiment, CGTase variants showing an 
increased product Specificity with respect to the production 
of C-cyclodextrin are provided, in which variants one or 
more of the amino acid residues corresponding to the 
following positions have been introduced by Substitution 
and/or insertion (CGTase Numbering): 
(i) Position 47: 47F; 47K: 47R; 47W; or 47Y; 
(ii) Position 145: 145D; 145H; 145N; or 1450; 
(iii) Position 146: 146H, 146K; 146L; 146T; 146V; or 146Y; 
(iv) Position 147: 147C; 147D; 147E; 147N; 1470; 
(v) Position 196: 1960; 196E; 196F; 196G; 196H; 196I; 
196K; 196L; 196M; 196P; 196O; 196R; 196T, 196V; 
196W; or 196Y and/or 
(vi) Position 371: 371C; 371H; 371K; 371R; or 371T. 
In another preferred embodiment, CGTase variants show 
ing an increased product specificity with respect to the 
production of B-cyclodextrin are provided, in which variants 
one or more of the amino acid residues corresponding to the 
following positions have been introduced by Substitution 
and/or insertion (CGTase Numbering): 
(i) Position 47: 47C; 47D; 47E; 47F: 47G; 47I; 47N; 47P; 
47S; 47T; 47V; 47W, or 47Y, 
(ii) Position 145: 145D; 145I; 145N; or 145V: 
(iii) Position 147: 147E; 
(iv) Position 196: 196C; 196E; 196F; 196G; 196H; 196I; 
196K; 196L; 196M; 196P; 196O; 196R; 196T, 196V; 
196W; or 196Y and/or 
(v) Position 371: 371C; 371E; 371F; 371H; 371I; 371K; 
371L: 371M; 371O; 371R; 371T; 371V; or 371W. 
In yet another preferred embodiment, CGTase variants 
showing an increased product specificity with respect to the 
production of Y-cyclodextrin are provided, in which variants 
one or more of the amino acid residues corresponding to the 
following positions have been introduced by Substitution 
and/or insertion (CGTase Numbering): 
(i) Position 47: 47C; 47D; 47E; 47F: 47G; 47I; 47N; 47P; 
47S; 47T; 47V; 47W, or 47Y, 
(ii) Position 145: 145D; 145I; 145N; or 145V: 
(iii) Position 147: 147E; 
(iv) Position 196: 196C; 196E; 196F; 196G; 196H; 196I; 
196K; 196L; 196M; 196P; 196O; 196R; 196T, 196V; 
196W; or 196Y and/or 
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(v) Position 371: 371C; 371E; 371F; 371H; 371K; 371M; 
371Q; 371R; 371T or 371W. 
The CGTase variant of the invention may be derived from 
any CGTase enzyme found in nature. However, the CGTase 
variant of the invention preferably is derived from a micro 
bial enzyme, preferably a bacterial enzyme, and preferably 
the CGTase variant is derived from a strain of Bacillus, a 
strain of Brevibacterium, a strain of Clostridium, a strain of 
Corynebacterium, a Strain of Klebsiella, a Strain of 
Micrococcus, a Strain of Thermoanaerobium, a Strain of 
Thermoanaerobacter, a Strain of Thermoanaerobacterium, a 
Strain of Thermoanaerobacterium, or a Strain of Thermoac 
tinomyces. 
In a more preferred embodiment, the CGTase variant of 
the invention is derived from a strain of Bacillus autolyticus, 
a Strain of Bacillus cereus, a Strain of Bacillus circulans, a 
strain of Bacillus circulans var. alkalophilus, a strain of 
Bacillus coagulans, a Strain of Bacillus firmus, a Strain of 
Bacillus halophilus, a Strain of Bacillus macerans, a Strain of 
Bacillus megaterium, a Strain of Bacillus Ohibensis, a Strain 
of Bacillus Stearothermophilus, a strain of Bacillus Subtilis, 
a Strain of Klebsiella pneumonia, a Strain of Thermoanaero 
bacter ethanolicus, a strain of Thermoanaerobacter finnii, a 
strain of CloStridium thermoamylolyticum, a strain of 
Clostridium thermosaccharolyticum, or a strain of Thermoa 
naerobacterium thermosulfurigenes. 
In a most preferred embodiment, the CGTase variant of 
the invention is derived from the strain Bacillus sp. Strain 
1011, the strain Bacillus sp. Strain 38-2, the strain Bacillus 
sp. Strain 17-1, the strain Bacillus sp. 1-1, the strain Bacillus 
sp. Strain B1018, the strain Bacillus circulans Strain 8, the 
strain Bacillus circulans Strain 251, or the strain Thermoa 
naerobacter sp. ATCC 53627, or mutants or variants thereof. 
If the CGTase variant of the invention is derived from a 
Strain of Bacillus circulans, one or more of the amino acid 
residues corresponding to the following positions may be 
introduced: 
(ii) Position S145: S145D; S145H; S145I; S145N; S145O; 
or S145V; 
(iii) Position S146: S146H, S146K; S146L; S146T; S146V; 
or S146Y; 
(iv) Position D147: D147C; D147E; D147N; D147O; (v) 
Position D196: D196C; D196E, D196F; D196G; D196H, 
D196I; D196K; D196L, D196M; D196P; D196O; 
D196R; D196T; D196V; D196W; or D196Y and/or (vi) 
Position D371; D371C; D371E; D371F; D371H; D371I; 
D371K; D371L: D371M; D371Q; D371R; D371T; 
D371V; or D371W. 
Preferably the CGTase variant is derived from Bacillus 
circulans Strain 251, or a mutant or a variant thereof. 
If the CGTase variant is derived from a strain of Ther 
moanaerobacter sp., one or more of the amino acid residues 











(iv) Position T147: T147C; T147D, T147E; T147N; T147O; 
(v) Position D196: D196C; D196E; D196F; D196G; 
D196H; D196I; D196K; D196L; D196M; D196P; 
D196O; D196R; D196T, D196V; D196W; or D196Y 
and/or 
(vi) Position D371: D371C; D371E; D371F; D371H: 
D371I; D371K; D371L: D371M; D371Q; D371R; 
D371T D371V; or D371W. 
Preferably the CGTase variant is derived from the strain 
Thermoanaerobacter sp. ATCC 53627, or a mutant or a 
variant thereof. 
Example 1 describes the construction of T thermosulfu 
rigenes CGTase variants Asp196His (D196H) and 
Asp37Arg (D371R) with modified product specificity, in 
which Site-directed mutagenesis has lead to an altered num 
ber of hydrogen bonds in the subsite of the active site cleft. 
The variants are derived from a Thermoanaerobacter ther 
mosulfurigenes EM1 CGTase (i.e. the wild-type), obtained 
as described by Haeckel and Bahl Haeckel, K., and Bahl, H. 
(1989) FEMS Microbiol. Lett. 60,333-338 or Knegtel R. M. 
A., Wind R. D., Rozeboom H. J., Kalk K. H., Buitelaar R. 
M., Dijkhuizen L., Dijkstra B. W. J. Mol. Biol. 256:611-622 
(1996). 
In another preferred embodiment, the CGTase variant of 
the invention comprises one or more of the following amino 




















If the CGTase variant is derived from a strain of Bacillus 
circulans one or more of the following amino acid residues 
may be introduced: 
US 6,777.215 B2 
(xvi) S145D/S146R; (xvii) S145D/S146E; 
(xviii) R47K/D371R; 
Preferably the CGTase variant is derived from Bacillus 
circulans Strain 251, or a mutant or a variant thereof. 
If the CGTase variant is derived from a strain of Ther 
moanaerobacter sp., one or more of the following amino 
acid residues may be introduced: 
Preferably the CGTase variant is derived from the strain 
Thermoanaerobacter sp. ATCC 53627, or a mutant or a 
variant thereof. 
In a further aspect the invention relates to the use of a 
CGTase variant of the invention for increasing the C. or f3 or 
Y-cyclodextrin content of the final cyclodextrin product of 
cyclodextrins processes. 
In a final aspect the invention relates to a method of 
increasing the product Specificity with respect to the pro 
duction of C. or B or Y-cyclodextrins, wherein one or more 
amino acid residues, corresponding to the positions of the 
CGTase variants of the invention mentioned above, have 
been introduced by Substitution and/or insertion. 
EXAMPLES 
Example 1 
Construction of T thermosulfurigenes CGTase variants 
with modified product specificity. 
Bacterial Strains, plasmids and growth conditions 
Escherichia coli JM109 endA1 recA1 gyrA96 thi 
hsdR17(rK-mK+) is relA1 supE44 (lac-proAB) F" traD36 
proAB lacIqZ M15 (Yanish-Perron et al. 1985 Gene 33, 
103-119) was used for recombinant DNA manipulations. 
Escherichia coli PC1990 (Lazzaroni and Portalier 1979 
FEMS Microbiol. Lett. 5, 411-416), known to leak peri 
plasmic proteins into the Supernatant because of a mutation 
in its tolB locus, was used for production of CGTase 
(mutant) proteins. Plasmid pCT2, a derivative of puC18 
containing the amy. A gene of Thermoanaerobacterium ther 
mosulfurigenes EM1 (Knegtel R. M. A., Wind R. D., Roze 
boom H. J., Kalk K. H., Buitelaar R. M., Dijkhuizen L., 
Dijkstra B. W. J. Mol. Biol. 256:611-622 (1996)), was used 
for site-directed mutagenesis, Sequencing and expression of 
the CGTase (mutant) proteins. Plasmid-carrying bacterial 
strains were grown on LB medium in the presence of 100 
ug/ml amplicillin. When appropriate, IPTG (isopropyl-B-D- 
thiogalacto-pyranoside) was added at a concentration of 0.1 













DNA manipulations and transformation of E. coli were 
essentially as described by Sambrook et al. Sambrook, J., 
Fritsch, E. J., and Maniatis, T. (1989) Molecular cloning: a 
laboratory manual, Cold Spring Harbor Laboratory Press, 
New York. Transformation of E. coli by electroporation was 
performed using the Bio-Rad gene pulser apparatus (Bio 
Rad, Veenendaal, The Netherlands). The selected conditions 
were 2.5 kV, 25 uF and 200 S2. 
Site-directed mutagenesis 
Mutant CGTase genes were constructed via a double PCR 
method using the Pful DNA polymerase from Stratagene 
(Westburg, Leusden, The Netherlands). A first PCR reaction 
was carried out with the mutagenesis primer for the coding 
strand plus a primer 195-715 bp downstream on the tem 
plate Strand. The reaction product was Subsequently used as 
primer in a Second PCR reaction together with a primer 
295-815 bp upstream on the coding strand. The product of 
the last reaction was cut with Nicol and MunI, and 
exchanged with the corresponding fragment (900 bp) from 
the vector pCT2. The resulting (mutant) plasmid was trans 
formed to E. coli JM109 for sequencing and E. coli PC1990 
for production of the (mutant) proteins. The following 
oligonucleotides were used: 
D 196H 5'- C GTAACTTATTTCATTTAG CA 
GATCTAAATCAACAG-3 (SEQ ID No. 1) 
D 371 R 5'- GAC AG G CAATG GAC GT CC 
TTATAATAGAGC-3' (SEQ ID NO. 2). 
Successful mutations resulted in the underlined restriction 
sites (Bg111 for D196H and AatII for D371R), which 
allowed quick Screening of transformants. Mutations were 
verified by DNA sequencing (Sanger et al. 1977 Proc. Natl. 
Sci. USA 74, 5463-5467). All 900 bp on the MunI-NcoI 
fragment obtained by PCR were checked by DNA 
Sequencing. 
Production and purification of CGTase proteins 
For production of CGTase proteins, E. coli PC1990 was 
grown in a 2-liter fermentor at pH 7.0 and 30 C. The medium 
contained 2% (w/w) tryptone (Oxoid, Boom BV, Meppel, 
The Netherlands), 1% (w/w) yeast extract (Oxoid), 1% 
(w/w) sodium chloride, 1% (w/w) casein hydrolysate 
(Merck, Darmstadt, Germany), 100 tug/l amplicillin and 0.1 
mM IPTG. Growth was monitored by measuring the optical 
density at 450 nm. When the optical density at 450 nm 
reached 2 to 3, an extra amount of 50g tryptone was added 
to the fermentor. Cells were harvested after 20-24 hours of 
growth (8,000 g, 30 minutes, 40° C), at an optical density 
of 8-12, and the Supernatant was used for further purification 
of the CGTases. Supernatant was directly applied to an 
C.-CD-sepharose-6FF affinity column (Monma et al. 1988 
Biotechnol. Bioeng. 32, 404–407). After washing the col 
umn with 10 mM sodium acetate (pH 5.5), the CGTase was 
eluted with the same buffer supplemented with 1% (w/w) 
C.-CD. Purity and molecular weight of the CGTase (mutant) 
proteins were checked on SDS-PAGE (Wind et al. 1995 
Appl. Environ. Microb. 61, 1257–1265). Protein concentra 
tions were determined by the method of Bradford, using the 
Coomassie protein assay reagent of Pierce (Pierce Europe 
by, Oud-Beijerland, The Netherlands). 
Enzyme assays 
All assays were standardly performed at pH 6.0 and 500 
C. Cyclization and Saccharifying assays were performed as 
described by Penninga et al. (Penninga, D., Strokopytov, B., 
Rozeboom, H. J., Lawson, C. L., Dijkstra, B. W., Bergsma, 
J., and Dijkhuizen, L. (1995) Biochemistry 34,3368–3376). 
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Units for the different reactions were defined as the amount 
of enzyme producing 1 umol of Substrate at pH 6.0 and 50 
C. 
HPLC product analysis 
Formation of cyclodextrins was measured under indus 
trial process conditions by incubation of 0.1 U/ml CGTase (B-CD forming activity) with 10% Paselli WA4 (pregelatinized drum-dried Starch with a high degree of 
polymerization; AVEBE, The Netherlands) in 10 mM 
sodium citrate buffer (pH 6.0) at 60° C. for 45 hours. 
Samples were taken at regular time intervals and boiled for 
10 minutes. Products formed were analyzed by HPLC, using 
a 25-cm Econosil-NH2 10 um column (Alltech Nederland 
bv, Breda, The Netherlands) eluted with acetonitrile-water 
(65:45) at 1 ml/minute. Products were detected by a refrac 
tive index detector (Waters 410, Waters Chromatography 
Division, Milford, USA). The temperature of the flow cell 
and column was set at 50 C., to avoid possible precipitation 
of Starch. Formation of linear products was directly ana 
lyzed. Formation of CD's was analyzed after incubation of 
the samples with an appropriate amount off-amylase (type 
I-B from Sweet potato, Sigma, Boom BV, Meppel, The 
Netherlands). 
Cyclodextrin product specificity 
In order to change the product specificity of Thermoa 
naerobacterium CGTase, we replaced Asp196 by His 
(D196H) and Asp371 by Arg (D371R). In mutant D196H 
production of C-CD was increased at the expense of the 
production of B-CD when compared to the wild-type 
CGTase (FIG. 2). The cyclodextrin product ratio was 
changed from 28:58:14 (C.: B:y) for the wild-type CGTase to 
35:49:16 for mutant D196H (Table 1). This is according to 
expectations on the basis of the Structural work. By the 
replacement of Asp197 by His a larger residue is introduced, 
this would block the So-called Straight Substrate binding 
mode. Furthermore, His 197 is probably also able to form 
hydrogen bonds with the substrate bound in the “bent mode. 
These results lean more vigour to the theory that the bent 
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conformation is correlated with C-cyclodextrin production, 
and show that it can be used to rationally engineer a CGTase 
with desired product specificity. 
TABLE 1. 
Starch conversion of T. thermosulfurigenes wild-type and 
mutant CGTase proteins. Proteins (0.1 U/ml f-CD forming activity) 
were incubated for 45 H at pH 6.0 and 60° C. with 10% Paselli WA4. 
Product Ratio Conversion 
Cyclization (%) of Starch 
activity (U/ml C. B Y into cyclodextrins (%) 
Wild- 163 28 S8 14 35 
type 
D196H 144 35 49 16 37 
D371R 14 6 68 26 29 
Asp 371 has a very important role in Substrate binding at 
subsite 2, both in the BC251 and Tabium CGTase. Replace 
ment of Asp371 by Arg resulted in the introduction of a very 
bulky amino acid, which would probably interfere severely 
with binding of all kinds of substrates at subsite 2, thereby 
explaining the overall decrease of activity. Apart from this 
low activity, the product ratio changed from 28:58:14 for the 
wild-type enzyme to 6:68:26 for mutant D371H (Table 1, 
FIG. 2). This Suggests that the cyclisation reaction leading to 
a C-cyclodextrin is more hampered by the Arg 371 than the 
other cyclisation reactions. Probably this bulky residue is 
sterically hindering the “bent conformation. These results 
show that the Tabium CGTase can changed from a C/B- 
cyclodextrin producer to a B/y-cyclodextrin producer by just 
one mutation, illustrating the feasibility of CGTase protein 
engineering. 
The invention is further illustrated with reference to the 
following examples which are not intended to be in any way 
limiting to the Scope of the invention as claimed. 
Cys Gly. Thr Ala Ala Cys Thr Thr Ala Thr Thr Thr Cys Ala Thir Thr 
1 5 10 15 
Thir Ala Gly Cys Ala Gly Ala Thr Cys Thr Ala Ala Ala Thr Cys Ala 
30 2O 25 
Ala Cys Ala Gly 
35 
SEQ ID NO 2 
LENGTH 30 
TYPE PRT 
ORGANISM: Artificial Sequence 
FEATURE 
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-continued 
<223> OTHER INFORMATION: synthetic 
<221 NAME/KEY: misc feature 
<223> OTHER INFORMATION: D371R oligo" 
<400 SEQUENCE: 2 
Gly Ala Cys Ala Gly Gly Cys Ala Ala Thr Gly Gly Ala Cys Gly Thr 
1 5 10 
Cys Cys Thr Thr Ala Thr Ala Ala Thr Ala Gly Ala Gly Cys 
30 2O 25 
What is claimed is: 
1. A cyclomaltodextrin glucanotransferase variant having 
an amino acid Sequence which differs from the amino acid 
Sequence of a parent cyclomaltodextrin glucanotransferase, 
wherein the parent cyclomaltodextrin glucanotraneferase is 
a Bacillus cyclomaltodextrin glucanotransferase and the 
difference between the amino acid Sequence of the cyclo 
maltodextrin glucenotransferase variant and the amino acid 
Sequence of the parent cyclomaltodextrin glucanotransferase 
comprises one or more of the following: 
47C; 47D; 47TE; 47F; 47G; 47I; 47K; 47N; 47P; 47S; 
47T; 47V; 47W, 47Y; 
145D; 145H; 145I; 145N; 145O; 145V: 
146H, 146L, 146T; 146V; 146Y; 
147C; 147E; 147N; 147O; 
196C; 196E, 196F; 196H, 196I; 196K; 196M; 196P; 
196O; 196R; 196T, 196V; 196W; 196Y; and 
371C; 371F; 371H; 371K; 371M; 371R; 371T 371W: 
wherein each position corresponds to the position of the 
amino acid Sequence of the mature Cyclomaltodextrin glu 
canotransferase obtained from Bacillus circulans strain 251. 
2. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the parent cyclomaltodextrin glucanotrans 
ferase is cyclomaltodextrin glucanotransferase is derived 
from a Bacillus Selected from the group consisting of 
Bacillus autolyticus, Bacillus cereus, Bacillus circulans, 
Bacillus circulans var. alkalophilus, Bacillus coagulans, 
Bacillus firmus, a strain of Bacillus halophilus, Bacillus 
macerans, Bacillus megaterium, Bacillus Ohibensis, Bacillus 
Stearothermophilus, Bacilius Subtilis. 
3. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the parent cyclomaltodextrin glucanotrans 
ferase is derived from a strain of Bacillus circulans or a 
mutant or a variant thereof. 
4. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the parent cyclomaltodextrin glucanotrans 
ferase is derived from a strain of Bacillus Stearothermophi 
lus. 
5. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 47C; 47D; 47E; 47F, 47G; 47I; 47K; 47N; 47P; 
47S; 47T; 47V; 47W, or 47Y. 
6. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 145D; 145H; 145I; 145N; 145O; or 145V. 
7. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 146H, 146L; 146T; 146V; or 146Y. 
8. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 147C; 147E; 147N; or 147O. 
9. The cyclomaltodextrin glucanotransferase variant of 











comprises 196C; 196E, 196F; 196H; 196I; 196K; 196M; 
196P; 1960; 196R; 196T; 196V; 196W; or 196Y. 
10. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 196H. 
11. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises 371C; 371F; 371H; 371K; 371M; 371R; 371T; or 
371 W. 
12. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises D371R. 
13. The cyclomaltodextrin glucanotransferase variant of 





















14. The cyclomaltodextrin glucanotransferase variant of 
claim 1, wherein the difference in amino acid positions 
comprises: 
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13 14 
S145D/E146R/T147D/D196H; 15. A method of producing a cyclodextrin, comprising 
S145D/T147D/D196H; treating a Starch with a cyclomaltodextrin glucanotrans 
S145D/E146R/T147D/D196H/D371R; ferase variant of claim 1. 
S145D/E146R/T147D/D196H/D371R; 5 16. The method of claim 15, wherein the cyclodextrin is 
S145E/E146V/T147N; a C-cyclodextrin. 
S145E/T147N, 17. The method of claim 15, wherein the cyclodextrin is 
s a B-cyclodextrin. 
its "it". 18. The method of claim 15, wherein the cyclodextrin is 
10 a Y-cyclodextrin. 
K47R/D371R; or 
K47R/D196H. k . . . . 
